| Yanwei Gao,Wei Luan,Wenxin Li,Baoqing Jia. The efficacy of capecitabine and temozolomide against neuroendocrine carcinomas. Oncol Transl Med, 2018, 4: 176-178. |
| The efficacy of capecitabine and temozolomide against neuroendocrine carcinomas |
| Received:June 15, 2018 Revised:June 15, 2018 |
| View Full Text View/Add Comment Download reader |
| KeyWord:temozolomide, capecitabine, neuroendocrine;carcinomas |
| Author Name | Affiliation | Department | | Yanwei Gao | Departments of Surgial Oncology, Inner Mongolia People's Hospital, Inner Mongolia 010017, China | Departments of Surgial Oncology | | Wei Luan | Departments of Oncology, Inner Mongolia People's Hospital, Inner Mongolia 010017, China | Departments of Oncology | | Wenxin Li | Departments of Oncology, Inner Mongolia People's Hospital, Inner Mongolia 010017, China | Departments of Oncology | | Baoqing Jia | Departments of Surgial Oncology, Inner Mongolia People's Hospital, Inner Mongolia 010017, China | Departments of Surgial Oncology |
|
| Hits: 6048 |
| Download times: 7122 |
| Abstract: |
| Objective Neuroendocrine carcinomas (NECs) are resistant to currently available chemotherapy agents,
and its therapeutic options are limited. Preclinical data have suggested synergy between capecitabine and
temozolomide (CAPTEM). Therefore, we evaluated the efficacy and safety of CAPTEM in patients with
metastatic NECs who have failed prior therapies.
Methods A retrospective review was conducted on seven patients with metastatic NECs for whom
platinum-based chemotherapies and hepatic chemoembolization failed. Patients received capecitabine
(1000 mg twice daily on days 1-14) and temozolomide (150–200 mg/m2 once daily on days 10–14) every
28 days. Tumor assessments were performed every two cycles.
Results Among the seven patients treated, two achieved partial remission and four achieved stable
disease. The total response rate was 29%, and the clinical benefit was 86%. Median progression-free
survival was 10 (range: 8–14) months. The most common toxicities were grade 1 and 2 neutropenia, grade
1 fatigue, and grade 1 and 2 hand-foot syndrome. No grade 4 toxicities or treatment-related deaths were
observed.
Conclusion Our study showed that the CAPTEM regimen is an effective and well-tolerated salvage
option for NECs. Further prospective studies are warranted to evaluate optimal combinations of the
CAPTEM regimen for NECs. |
| Close |
|
|
|